Vita Coco Q3 beats and raises FY26 guidance, but valuation remains rich

What happened

Vita Coco reported third-quarter 2026 net sales of $244 million, up 34% year-over-year, with organic growth of 18%, driven by a 15% increase in Vita Coco Coconut Water sales. Net income rose $11 million to $35 million, and adjusted EBITDA jumped $21 million to $53 million. The company raised full-year 2026 guidance to net sales of $810-820 million and adjusted EBITDA of $170-175 million, reflecting continued momentum. The DeepValue master report, last updated in late 2025, had flagged tariff-driven margin compression, intensified competition, and a rich valuation as key concerns. While these results suggest resilient demand and successful execution, the stock's premium multiple remains a significant hurdle relative to intrinsic value estimates.

Implication

Investors should reassess the bear thesis: the company has delivered accelerating growth and expanding profitability, directly countering earlier worries about tariff impacts and category maturity. However, the share price likely remains elevated, so any stumble in growth or margin could trigger a sharp correction. Watch for sustained gross margin improvement and continued branded volume growth in coming quarters. The raised guidance indicates management confidence, but execution risks around supply chain and competition persist. A disciplined approach would be to wait for a better entry point or clearer evidence that the premium multiple is justified by durable cash-flow growth.

Thesis delta

The latest results significantly challenge the prior 'POTENTIAL SELL' stance, as the company has shown robust growth and profitability that appear to overcome tariff and competitive headwinds. The guidance raise suggests the company is on a stronger trajectory than previously modeled. However, valuation remains elevated, and the risks of margin compression and category maturation have not disappeared, so the thesis shifts to a more balanced view, perhaps closer to 'WAIT' or 'POTENTIAL BUY' on weakness.